Trial
NCT03298958
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
—
Condition
Bladder Cancer
Intervention
Rapamycin
Why stopped
No funding was received, no subjects were enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-12